| Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis N Ahmad, SD Ahuja, OW Akkerman, JWC Alffenaar, LF Anderson, ... The Lancet 392 (10150), 821-834, 2018 | 516 | 2018 |
| Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study SE Borisov, K Dheda, M Enwerem, RR Leyet, L D'Ambrosio, R Centis, ... European Respiratory Journal 49 (5), 2017 | 367 | 2017 |
| Worldwide effects of coronavirus disease pandemic on tuberculosis services, January–April 2020 GB Migliori, PM Thong, O Akkerman, JW Alffenaar, F Álvarez-Navascués, ... Emerging infectious diseases 26 (11), 2709, 2020 | 225 | 2020 |
| MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network GB Migliori, S Tiberi, A Zumla, E Petersen, JM Chakaya, C Wejse, ... International Journal of Infectious Diseases 92, S15-S25, 2020 | 221 | 2020 |
| Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report S Borisov, E Danila, A Maryandyshev, M Dalcolmo, S Miliauskas, L Kuksa, ... European Respiratory Journal 54 (6), 2019 | 186 | 2019 |
| Clinical standards for the assessment, management and rehabilitation of post-TB lung disease GB Migliori, FM Marx, N Ambrosino, E Zampogna, HS Schaaf, ... The International Journal of Tuberculosis and Lung Disease 25 (10), 797-813, 2021 | 135 | 2021 |
| Tuberculosis and COVID-19 co-infection: description of the global cohort TB/COVID-19 Global Study Group European Respiratory Journal 59 (3), 2022 | 123 | 2022 |
| Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR-and XDR-TB S Tiberi, MC Payen, G Sotgiu, L D'Ambrosio, VA Guizado, JW Alffenaar, ... European Respiratory Journal 47 (4), 1235-1243, 2016 | 120 | 2016 |
| Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis F Fregonese, SD Ahuja, OW Akkerman, D Arakaki-Sanchez, I Ayakaka, ... The lancet respiratory medicine 6 (4), 265-275, 2018 | 103 | 2018 |
| Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR-and XDR-TB S Tiberi, G Sotgiu, L D'Ambrosio, R Centis, MA Arbex, EA Arrascue, ... European Respiratory Journal 47 (6), 1758-1766, 2016 | 96 | 2016 |
| Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics S Ghimire, MS Bolhuis, MGG Sturkenboom, OW Akkerman, ... European Respiratory Journal 47 (6), 1867-1869, 2016 | 82 | 2016 |
| Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017. Treatment correlates of successful outcomes in pulmonary multidrug-resistant … N Ahmad, SD Ahuja, OW Akkerman, JC Alffenaar, LF Anderson, ... Lancet 392 (10150), 821-834, 2018 | 79 | 2018 |
| Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment MS Bolhuis, OW Akkerman, MGG Sturkenboom, S Ghimire, S Srivastava, ... Clinical Infectious Diseases 67 (suppl_3), S327-S335, 2018 | 77 | 2018 |
| The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ family M Hoppentocht, OW Akkerman, P Hagedoorn, HW Frijlink, AH de Boer European Journal of Pharmaceutics and Biopharmaceutics 90, 8-15, 2015 | 69 | 2015 |
| Microevolution of Mycobacterium tuberculosis in a Tuberculosis Patient SAM Al-Hajoj, O Akkerman, I Parwati, S Al-Gamdi, Z Rahim, ... Journal of Clinical Microbiology 48 (10), 3813-3816, 2010 | 69 | 2010 |
| Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis OW Akkerman, OFF Odish, MS Bolhuis, WCM de Lange, HPH Kremer, ... Clinical Infectious Diseases 62 (4), 523-524, 2016 | 66 | 2016 |
| Bedaquiline and delamanid combination treatment of 5 patients with pulmonary extensively drug-resistant tuberculosis A Maryandyshev, E Pontali, S Tiberi, O Akkerman, S Ganatra, ... Emerging infectious diseases 23 (10), 1718, 2017 | 62 | 2017 |
| Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study O Akkerman, A Aleksa, JW Alffenaar, NH Al-Marzouqi, M Arias-Guillén, ... International journal of infectious diseases 83, 72-76, 2019 | 58 | 2019 |
| Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring SHJ van den Elsen, LM Oostenbrink, SK Heysell, D Hira, DJ Touw, ... Therapeutic drug monitoring 40 (1), 17-37, 2018 | 49 | 2018 |
| Clinical standards for the dosing and management of TB drugs JWC Alffenaar, SL Stocker, LD Forsman, A Garcia-Prats, SK Heysell, ... The International Journal of Tuberculosis and Lung Disease 26 (6), 483-499, 2022 | 48 | 2022 |
